• Policy
• AbbVie Korea will discontinue supply of Kaletra
• by Lee, Tak-Sun Feb 27, 2024 05:45am

• Company
• K-biopharma starts trials with bispecific antibodies
• by Son, Hyung-Min Feb 27, 2024 05:45am

• Policy
• Expedited domestic supply of suspended essential medicines
• by Lee, Hye-Kyung Feb 27, 2024 05:45am

• Company
• Reimbursement for novel CMV drug Livtencity imminent in KOR
• by Eo, Yun-Ho Feb 27, 2024 05:45am

• Policy
• Delayed actual transaction price cuts slash expected savings
• by Lee, Tak-Sun Feb 26, 2024 05:25am

• Company
• Shingrix leads shingles vaccine mkt…occupies 44% of mkt
• by Chon, Seung-Hyun Feb 26, 2024 05:24am

• Company
• Samsung Bioepis’s Eylea biosimilar Afilivu approved in KOR
• by Son, Hyung-Min Feb 26, 2024 05:24am

• Company
• Eylea continues to lead AMD mkt despite new competition
• by Son, Hyung-Min Feb 26, 2024 05:24am

• Company
• Kay Bae appointed as KRPIA chair, also overseeing NZ, AUS
• by Eo, Yun-Ho Feb 26, 2024 05:24am

• Company
• New Alzheimer’s drug Leqembi closer to drug marketing
• by Eo, Yun-Ho Feb 26, 2024 05:24am